StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)

Wed, 15 Jul 2026 07:38:43 -0400

H.C. Wainwright analyst Andres Maldonado reiterated a Buy rating and $40.00 price target on Syndax Pharmaceuticals (NASDAQ: SNDX).

The analyst commented: "Yesterday, we attended Syndax’s R&D Day, which showcased two new assets, SNDX-62122 and SNDX-4321, that we believe could provide meaningful long-term value creation beyond the established Revuforj and Niktimvo franchises. SNDX-62122 is an internally developed, next-generation menin inhibitor being advanced initially in myelofibrosis and designed to offer higher potency, improved selectivity, optimized pharmacokinetics, and a potentially more combinable profile than parent molecule revumenib. Compelling preclinical data identified menin as a novel dependency in the atypical megakaryocytes and early megakaryocyte progenitors

Form 8-K Syndax Pharmaceuticals For: Jul 14

Tue, 14 Jul 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260714/26765386.html

Form 8-K Syndax Pharmaceuticals For: Jul 14

Tue, 14 Jul 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260714/26765386.html

Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event

Tue, 14 Jul 2026 08:00:00 -0400

– Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs –

– SNDX-62122, a next-generation menin inhibitor, selected for development in MF, building on compelling preclinical results observed with revumenib in MF –

– SNDX-62122 is the first candidate from the Company’s library of internally developed and wholly owned next-generation menin inhibitors that the Company plans to deploy in new areas –

– Phase 2 trial of axatilimab in IPF on track for topline data in 4Q26 –

– R&D Event featuring three

Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event

Tue, 14 Jul 2026 08:00:00 -0400

– Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs –

– SNDX-62122, a next-generation menin inhibitor, selected for development in MF, building on compelling preclinical results observed with revumenib in MF –

– SNDX-62122 is the first candidate from the Company’s library of internally developed and wholly owned next-generation menin inhibitors that the Company plans to deploy in new areas –

– Phase 2 trial of axatilimab in IPF on track for topline data in 4Q26 –

– R&D Event featuring three

Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event

Tue, 14 Jul 2026 08:00:00 -0400

– Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs –

– SNDX-62122, a next-generation menin inhibitor, selected for development in MF, building on compelling preclinical results observed with revumenib in MF –

– SNDX-62122 is the first candidate from the Company’s library of internally developed and wholly owned next-generation menin inhibitors that the Company plans to deploy in new areas –

– Phase 2 trial of axatilimab in IPF on track for topline data in 4Q26 –

– R&D Event featuring three

Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event

Tue, 14 Jul 2026 08:00:00 -0400

– Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs –

– SNDX-62122, a next-generation menin inhibitor, selected for development in MF, building on compelling preclinical results observed with revumenib in MF –

– SNDX-62122 is the first candidate from the Company’s library of internally developed and wholly owned next-generation menin inhibitors that the Company plans to deploy in new areas –

– Phase 2 trial of axatilimab in IPF on track for topline data in 4Q26 –

– R&D Event featuring three

Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event

Tue, 14 Jul 2026 08:00:00 -0400

– Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs –

– SNDX-62122, a next-generation menin inhibitor, selected for development in MF, building on compelling preclinical results observed with revumenib in MF –

– SNDX-62122 is the first candidate from the Company’s library of internally developed and wholly owned next-generation menin inhibitors that the Company plans to deploy in new areas –

– Phase 2 trial of axatilimab in IPF on track for topline data in 4Q26 –

– R&D Event featuring three

Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event

Tue, 14 Jul 2026 08:00:00 -0400

– Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs –

– SNDX-62122, a next-generation menin inhibitor, selected for development in MF, building on compelling preclinical results observed with revumenib in MF –

– SNDX-62122 is the first candidate from the Company’s library of internally developed and wholly owned next-generation menin inhibitors that the Company plans to deploy in new areas –

– Phase 2 trial of axatilimab in IPF on track for topline data in 4Q26 –

– R&D Event featuring three

Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event

Tue, 14 Jul 2026 08:00:00 -0400

– Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs –

– SNDX-62122, a next-generation menin inhibitor, selected for development in MF, building on compelling preclinical results observed with revumenib in MF –

– SNDX-62122 is the first candidate from the Company’s library of internally developed and wholly owned next-generation menin inhibitors that the Company plans to deploy in new areas –

– Phase 2 trial of axatilimab in IPF on track for topline data in 4Q26 –

– R&D Event featuring three

Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event

Tue, 14 Jul 2026 08:00:00 -0400

– Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs –

– SNDX-62122, a next-generation menin inhibitor, selected for development in MF, building on compelling preclinical results observed with revumenib in MF –

– SNDX-62122 is the first candidate from the Company’s library of internally developed and wholly owned next-generation menin inhibitors that the Company plans to deploy in new areas –

– Phase 2 trial of axatilimab in IPF on track for topline data in 4Q26 –

– R&D Event featuring three

Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event

Tue, 14 Jul 2026 08:00:00 -0400

– Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs –

– SNDX-62122, a next-generation menin inhibitor, selected for development in MF, building on compelling preclinical results observed with revumenib in MF –

– SNDX-62122 is the first candidate from the Company’s library of internally developed and wholly owned next-generation menin inhibitors that the Company plans to deploy in new areas –

– Phase 2 trial of axatilimab in IPF on track for topline data in 4Q26 –

– R&D Event featuring three

Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event

Tue, 14 Jul 2026 08:00:00 -0400

– Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs –

– SNDX-62122, a next-generation menin inhibitor, selected for development in MF, building on compelling preclinical results observed with revumenib in MF –

– SNDX-62122 is the first candidate from the Company’s library of internally developed and wholly owned next-generation menin inhibitors that the Company plans to deploy in new areas –

– Phase 2 trial of axatilimab in IPF on track for topline data in 4Q26 –

– R&D Event featuring three

Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event

Tue, 14 Jul 2026 08:00:00 -0400

– Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs –

– SNDX-62122, a next-generation menin inhibitor, selected for development in MF, building on compelling preclinical results observed with revumenib in MF –

– SNDX-62122 is the first candidate from the Company’s library of internally developed and wholly owned next-generation menin inhibitors that the Company plans to deploy in new areas –

– Phase 2 trial of axatilimab in IPF on track for topline data in 4Q26 –

– R&D Event featuring three

Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event

Tue, 14 Jul 2026 08:00:00 -0400

– Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs –

– SNDX-62122, a next-generation menin inhibitor, selected for development in MF, building on compelling preclinical results observed with revumenib in MF –

– SNDX-62122 is the first candidate from the Company’s library of internally developed and wholly owned next-generation menin inhibitors that the Company plans to deploy in new areas –

– Phase 2 trial of axatilimab in IPF on track for topline data in 4Q26 –

– R&D Event featuring three

Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event

Tue, 14 Jul 2026 08:00:00 -0400

– Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs –

– SNDX-62122, a next-generation menin inhibitor, selected for development in MF, building on compelling preclinical results observed with revumenib in MF –

– SNDX-62122 is the first candidate from the Company’s library of internally developed and wholly owned next-generation menin inhibitors that the Company plans to deploy in new areas –

– Phase 2 trial of axatilimab in IPF on track for topline data in 4Q26 –

– R&D Event featuring three

Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event

Tue, 14 Jul 2026 08:00:00 -0400

– Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs –

– SNDX-62122, a next-generation menin inhibitor, selected for development in MF, building on compelling preclinical results observed with revumenib in MF –

– SNDX-62122 is the first candidate from the Company’s library of internally developed and wholly owned next-generation menin inhibitors that the Company plans to deploy in new areas –

– Phase 2 trial of axatilimab in IPF on track for topline data in 4Q26 –

– R&D Event featuring three

Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event

Tue, 14 Jul 2026 08:00:00 -0400

– Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs –

– SNDX-62122, a next-generation menin inhibitor, selected for development in MF, building on compelling preclinical results observed with revumenib in MF –

– SNDX-62122 is the first candidate from the Company’s library of internally developed and wholly owned next-generation menin inhibitors that the Company plans to deploy in new areas –

– Phase 2 trial of axatilimab in IPF on track for topline data in 4Q26 –

– R&D Event featuring three

Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event

Tue, 14 Jul 2026 08:00:00 -0400

– Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs –

– SNDX-62122, a next-generation menin inhibitor, selected for development in MF, building on compelling preclinical results observed with revumenib in MF –

– SNDX-62122 is the first candidate from the Company’s library of internally developed and wholly owned next-generation menin inhibitors that the Company plans to deploy in new areas –

– Phase 2 trial of axatilimab in IPF on track for topline data in 4Q26 –

– R&D Event featuring three

Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event

Tue, 14 Jul 2026 08:00:00 -0400

– Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs –

– SNDX-62122, a next-generation menin inhibitor, selected for development in MF, building on compelling preclinical results observed with revumenib in MF –

– SNDX-62122 is the first candidate from the Company’s library of internally developed and wholly owned next-generation menin inhibitors that the Company plans to deploy in new areas –

– Phase 2 trial of axatilimab in IPF on track for topline data in 4Q26 –

– R&D Event featuring three

Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event

Tue, 14 Jul 2026 08:00:00 -0400

– Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs –

– SNDX-62122, a next-generation menin inhibitor, selected for development in MF, building on compelling preclinical results observed with revumenib in MF –

– SNDX-62122 is the first candidate from the Company’s library of internally developed and wholly owned next-generation menin inhibitors that the Company plans to deploy in new areas –

– Phase 2 trial of axatilimab in IPF on track for topline data in 4Q26 –

– R&D Event featuring three

Form 4 Syndax Pharmaceuticals For: Jul 08 Filed by: Metzger Michael A

Thu, 09 Jul 2026 16:54:00 -0400
si-local-file:///var/storage/secattach/20260709/26753792.html

Form 4 Syndax Pharmaceuticals For: Jul 08 Filed by: Metzger Michael A

Thu, 09 Jul 2026 16:54:00 -0400
si-local-file:///var/storage/secattach/20260709/26753792.html

Form 144 Syndax Pharmaceuticals Filed by: Metzger Michael A

Wed, 08 Jul 2026 16:39:00 -0400
si-local-file:///var/storage/secattach/20260708/26748031.html

Form 144 Syndax Pharmaceuticals Filed by: Metzger Michael A

Wed, 08 Jul 2026 16:39:00 -0400
si-local-file:///var/storage/secattach/20260708/26748031.html